Characterization and metabolic synthetic lethal testing in a new model of SDH-loss familial pheochromocytoma and paraganglioma

John Smestad, Oksana Hamidi, Lin Wang, Molly Nelson Holte, Fatimah Al Khazal, Luke Erber, Yue Chen, L James Maher III

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Succinate dehydrogenase (SDH)-loss pheochromocytoma and paraganglioma (PPGL) are tumors driven by metabolic derangement. SDH loss leads to accumulation of intracellular succinate, which competitively inhibits dioxygenase enzymes, causing activation of pseudohypoxic signaling and hypermethylation of histones and DNA. The mechanisms by which these alterations lead to tumorigenesis are unclear, however. In an effort to fundamentally understand how SDH loss reprograms cell biology, we developed an immortalized mouse embryonic fibroblast cell line with conditional disruption of Sdhc and characterize the kinetics of Sdhc gene rearrangement, SDHC protein loss, succinate accumulation, and the resultant hypoproliferative phenotype. We further perform global transcriptomic, epigenomic, and proteomic characterization of changes resulting from SDHC loss, identifying specific perturbations at each biological level. We compare the observed patterns of epigenomic derangement to another previously-described immortalized mouse chromaffin cell model of SDHB loss, and compare both models to human SDH-loss tumors. Finally, we perform analysis of SDHC synthetic lethality with lactate dehydrogenase A (LDHA) and pyruvate carboxylase (PCX), which are important for regeneration of NAD+ and aspartate biosynthesis, respectively. Our data show that SDH-loss cells are selectively vulnerable to LDH genetic knock-down or chemical inhibition, suggesting that LDH inhibition may be an effective therapeutic strategy for SDH-loss PPGL.

Original languageEnglish (US)
Pages (from-to)6109-6127
Number of pages19
JournalOncotarget
Volume9
Issue number5
DOIs
StatePublished - Jan 1 2018

Fingerprint

Paraganglioma
Succinate Dehydrogenase
Succinic Acid
Pheochromocytoma
Epigenomics
Pyruvate Carboxylase
Dioxygenases
Chromaffin Cells
Enzyme Activation
Gene Rearrangement
Aspartic Acid
NAD
Proteomics
Histones
Cell Biology
Islet cell tumor syndrome
Regeneration
Neoplasms
Carcinogenesis
Fibroblasts

Keywords

  • Epigenomics, proteomics
  • Lactate dehydrogenase
  • Synthetic lethality
  • Transcriptomics

ASJC Scopus subject areas

  • Oncology

Cite this

Characterization and metabolic synthetic lethal testing in a new model of SDH-loss familial pheochromocytoma and paraganglioma. / Smestad, John; Hamidi, Oksana; Wang, Lin; Holte, Molly Nelson; Al Khazal, Fatimah; Erber, Luke; Chen, Yue; Maher III, L James.

In: Oncotarget, Vol. 9, No. 5, 01.01.2018, p. 6109-6127.

Research output: Contribution to journalArticle

Smestad, John ; Hamidi, Oksana ; Wang, Lin ; Holte, Molly Nelson ; Al Khazal, Fatimah ; Erber, Luke ; Chen, Yue ; Maher III, L James. / Characterization and metabolic synthetic lethal testing in a new model of SDH-loss familial pheochromocytoma and paraganglioma. In: Oncotarget. 2018 ; Vol. 9, No. 5. pp. 6109-6127.
@article{fd54e9e4d2bd425e91ea8a2309300f28,
title = "Characterization and metabolic synthetic lethal testing in a new model of SDH-loss familial pheochromocytoma and paraganglioma",
abstract = "Succinate dehydrogenase (SDH)-loss pheochromocytoma and paraganglioma (PPGL) are tumors driven by metabolic derangement. SDH loss leads to accumulation of intracellular succinate, which competitively inhibits dioxygenase enzymes, causing activation of pseudohypoxic signaling and hypermethylation of histones and DNA. The mechanisms by which these alterations lead to tumorigenesis are unclear, however. In an effort to fundamentally understand how SDH loss reprograms cell biology, we developed an immortalized mouse embryonic fibroblast cell line with conditional disruption of Sdhc and characterize the kinetics of Sdhc gene rearrangement, SDHC protein loss, succinate accumulation, and the resultant hypoproliferative phenotype. We further perform global transcriptomic, epigenomic, and proteomic characterization of changes resulting from SDHC loss, identifying specific perturbations at each biological level. We compare the observed patterns of epigenomic derangement to another previously-described immortalized mouse chromaffin cell model of SDHB loss, and compare both models to human SDH-loss tumors. Finally, we perform analysis of SDHC synthetic lethality with lactate dehydrogenase A (LDHA) and pyruvate carboxylase (PCX), which are important for regeneration of NAD+ and aspartate biosynthesis, respectively. Our data show that SDH-loss cells are selectively vulnerable to LDH genetic knock-down or chemical inhibition, suggesting that LDH inhibition may be an effective therapeutic strategy for SDH-loss PPGL.",
keywords = "Epigenomics, proteomics, Lactate dehydrogenase, Synthetic lethality, Transcriptomics",
author = "John Smestad and Oksana Hamidi and Lin Wang and Holte, {Molly Nelson} and {Al Khazal}, Fatimah and Luke Erber and Yue Chen and {Maher III}, {L James}",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.23639",
language = "English (US)",
volume = "9",
pages = "6109--6127",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "5",

}

TY - JOUR

T1 - Characterization and metabolic synthetic lethal testing in a new model of SDH-loss familial pheochromocytoma and paraganglioma

AU - Smestad, John

AU - Hamidi, Oksana

AU - Wang, Lin

AU - Holte, Molly Nelson

AU - Al Khazal, Fatimah

AU - Erber, Luke

AU - Chen, Yue

AU - Maher III, L James

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Succinate dehydrogenase (SDH)-loss pheochromocytoma and paraganglioma (PPGL) are tumors driven by metabolic derangement. SDH loss leads to accumulation of intracellular succinate, which competitively inhibits dioxygenase enzymes, causing activation of pseudohypoxic signaling and hypermethylation of histones and DNA. The mechanisms by which these alterations lead to tumorigenesis are unclear, however. In an effort to fundamentally understand how SDH loss reprograms cell biology, we developed an immortalized mouse embryonic fibroblast cell line with conditional disruption of Sdhc and characterize the kinetics of Sdhc gene rearrangement, SDHC protein loss, succinate accumulation, and the resultant hypoproliferative phenotype. We further perform global transcriptomic, epigenomic, and proteomic characterization of changes resulting from SDHC loss, identifying specific perturbations at each biological level. We compare the observed patterns of epigenomic derangement to another previously-described immortalized mouse chromaffin cell model of SDHB loss, and compare both models to human SDH-loss tumors. Finally, we perform analysis of SDHC synthetic lethality with lactate dehydrogenase A (LDHA) and pyruvate carboxylase (PCX), which are important for regeneration of NAD+ and aspartate biosynthesis, respectively. Our data show that SDH-loss cells are selectively vulnerable to LDH genetic knock-down or chemical inhibition, suggesting that LDH inhibition may be an effective therapeutic strategy for SDH-loss PPGL.

AB - Succinate dehydrogenase (SDH)-loss pheochromocytoma and paraganglioma (PPGL) are tumors driven by metabolic derangement. SDH loss leads to accumulation of intracellular succinate, which competitively inhibits dioxygenase enzymes, causing activation of pseudohypoxic signaling and hypermethylation of histones and DNA. The mechanisms by which these alterations lead to tumorigenesis are unclear, however. In an effort to fundamentally understand how SDH loss reprograms cell biology, we developed an immortalized mouse embryonic fibroblast cell line with conditional disruption of Sdhc and characterize the kinetics of Sdhc gene rearrangement, SDHC protein loss, succinate accumulation, and the resultant hypoproliferative phenotype. We further perform global transcriptomic, epigenomic, and proteomic characterization of changes resulting from SDHC loss, identifying specific perturbations at each biological level. We compare the observed patterns of epigenomic derangement to another previously-described immortalized mouse chromaffin cell model of SDHB loss, and compare both models to human SDH-loss tumors. Finally, we perform analysis of SDHC synthetic lethality with lactate dehydrogenase A (LDHA) and pyruvate carboxylase (PCX), which are important for regeneration of NAD+ and aspartate biosynthesis, respectively. Our data show that SDH-loss cells are selectively vulnerable to LDH genetic knock-down or chemical inhibition, suggesting that LDH inhibition may be an effective therapeutic strategy for SDH-loss PPGL.

KW - Epigenomics, proteomics

KW - Lactate dehydrogenase

KW - Synthetic lethality

KW - Transcriptomics

UR - http://www.scopus.com/inward/record.url?scp=85040683247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040683247&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.23639

DO - 10.18632/oncotarget.23639

M3 - Article

AN - SCOPUS:85040683247

VL - 9

SP - 6109

EP - 6127

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 5

ER -